Loading…
Subtypes of antipsychotics and suicidal behavior in bipolar disorder
Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in...
Saved in:
Published in: | Journal of affective disorders 2012-12, Vol.143 (1), p.27-33 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3 |
container_end_page | 33 |
container_issue | 1 |
container_start_page | 27 |
container_title | Journal of affective disorders |
container_volume | 143 |
creator | Koek, Ralph J Yerevanian, Boghos I Mintz, Jim |
description | Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype. |
doi_str_mv | 10.1016/j.jad.2012.05.053 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1364765610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032712004363</els_id><sourcerecordid>1272723519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7rj6A7xIXwQvPVaSzheCIOsnLHhYPYd0usJm7Om0SffC_HszzKjgwSUFIfC8lZCnCHlOYUuByte77c4NWwaUbUHU4g_IhgrFWyaoekg2lREtcKYuyJNSdgAgjYLH5IIx1ZlKbsj7m7VfDjOWJoXGTUucy8HfpiX6Uo9DU9bo4-DGpsdbdxdTbuLU9HFOo8vNEEvKA-an5FFwY8Fn5_2SfP_44dvV5_b666cvV--uWy-4WlpNQwfUB8Ul152D0OvQMXCd1tohBmmEVE5oZEZxY3hvek6BGY8cayDwS_Lq1HfO6eeKZbH7WDyOo5swrcVSLjslhaRwP8pUXVxQcz9KlZYadEcrSk-oz6mUjMHOOe5dPlgK9qjE7mxVYo9KLIhavGZenNuv_R6HP4nfDirw8gy44t0Yspt8LH85KTtjJKvcmxOH9YvvImZbfMTJ4xAz-sUOKf73GW__SfsxTrFe-AMPWHZpzVN1Z6ktNWNvjrNzHB3KALoqjP8Cke27fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1178680841</pqid></control><display><type>article</type><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Elsevier</source><creator>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</creator><creatorcontrib>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</creatorcontrib><description>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2012.05.053</identifier><identifier>PMID: 22749157</identifier><identifier>CODEN: JADID7</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Affective disorders ; Aged ; Anticonvulsants ; Anticonvulsants - therapeutic use ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Antipsychotics ; Attempted suicide ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Bipolar affective disorder ; Bipolar disorder ; Bipolar Disorder - drug therapy ; Bipolar disorders ; Carbamazepine ; Conjunction ; Data processing ; Depression ; Dibenzothiazepines - therapeutic use ; Divalproex ; Female ; Hospitalization ; Hospitals ; Humans ; Lithium ; Male ; Medical sciences ; Middle Aged ; Mood ; Mood disorders ; Moods ; Neuroleptics ; Neuropharmacology ; olanzapine ; Pharmacology. Drug treatments ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; quetiapine ; Quetiapine Fumarate ; Retrospective Studies ; Risk factors ; Risperidone ; Risperidone - therapeutic use ; Suicidal behaviour ; Suicidal Ideation ; Suicide ; Suicide - prevention & control ; Suicide - psychology ; Suicide - statistics & numerical data ; Suicide, Attempted - prevention & control ; Suicide, Attempted - psychology ; Suicide, Attempted - statistics & numerical data ; Veterans</subject><ispartof>Journal of affective disorders, 2012-12, Vol.143 (1), p.27-33</ispartof><rights>2012</rights><rights>2015 INIST-CNRS</rights><rights>Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</citedby><cites>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,31000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26649962$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22749157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koek, Ralph J</creatorcontrib><creatorcontrib>Yerevanian, Boghos I</creatorcontrib><creatorcontrib>Mintz, Jim</creatorcontrib><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Affective disorders</subject><subject>Aged</subject><subject>Anticonvulsants</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Antipsychotics</subject><subject>Attempted suicide</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bipolar affective disorder</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Bipolar disorders</subject><subject>Carbamazepine</subject><subject>Conjunction</subject><subject>Data processing</subject><subject>Depression</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Divalproex</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lithium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood</subject><subject>Mood disorders</subject><subject>Moods</subject><subject>Neuroleptics</subject><subject>Neuropharmacology</subject><subject>olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>quetiapine</subject><subject>Quetiapine Fumarate</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Risperidone</subject><subject>Risperidone - therapeutic use</subject><subject>Suicidal behaviour</subject><subject>Suicidal Ideation</subject><subject>Suicide</subject><subject>Suicide - prevention & control</subject><subject>Suicide - psychology</subject><subject>Suicide - statistics & numerical data</subject><subject>Suicide, Attempted - prevention & control</subject><subject>Suicide, Attempted - psychology</subject><subject>Suicide, Attempted - statistics & numerical data</subject><subject>Veterans</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkk2LFDEQhoMo7rj6A7xIXwQvPVaSzheCIOsnLHhYPYd0usJm7Om0SffC_HszzKjgwSUFIfC8lZCnCHlOYUuByte77c4NWwaUbUHU4g_IhgrFWyaoekg2lREtcKYuyJNSdgAgjYLH5IIx1ZlKbsj7m7VfDjOWJoXGTUucy8HfpiX6Uo9DU9bo4-DGpsdbdxdTbuLU9HFOo8vNEEvKA-an5FFwY8Fn5_2SfP_44dvV5_b666cvV--uWy-4WlpNQwfUB8Ul152D0OvQMXCd1tohBmmEVE5oZEZxY3hvek6BGY8cayDwS_Lq1HfO6eeKZbH7WDyOo5swrcVSLjslhaRwP8pUXVxQcz9KlZYadEcrSk-oz6mUjMHOOe5dPlgK9qjE7mxVYo9KLIhavGZenNuv_R6HP4nfDirw8gy44t0Yspt8LH85KTtjJKvcmxOH9YvvImZbfMTJ4xAz-sUOKf73GW__SfsxTrFe-AMPWHZpzVN1Z6ktNWNvjrNzHB3KALoqjP8Cke27fw</recordid><startdate>20121220</startdate><enddate>20121220</enddate><creator>Koek, Ralph J</creator><creator>Yerevanian, Boghos I</creator><creator>Mintz, Jim</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>7QJ</scope></search><sort><creationdate>20121220</creationdate><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><author>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Affective disorders</topic><topic>Aged</topic><topic>Anticonvulsants</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Antipsychotics</topic><topic>Attempted suicide</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bipolar affective disorder</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Bipolar disorders</topic><topic>Carbamazepine</topic><topic>Conjunction</topic><topic>Data processing</topic><topic>Depression</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Divalproex</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lithium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood</topic><topic>Mood disorders</topic><topic>Moods</topic><topic>Neuroleptics</topic><topic>Neuropharmacology</topic><topic>olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>quetiapine</topic><topic>Quetiapine Fumarate</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Risperidone</topic><topic>Risperidone - therapeutic use</topic><topic>Suicidal behaviour</topic><topic>Suicidal Ideation</topic><topic>Suicide</topic><topic>Suicide - prevention & control</topic><topic>Suicide - psychology</topic><topic>Suicide - statistics & numerical data</topic><topic>Suicide, Attempted - prevention & control</topic><topic>Suicide, Attempted - psychology</topic><topic>Suicide, Attempted - statistics & numerical data</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koek, Ralph J</creatorcontrib><creatorcontrib>Yerevanian, Boghos I</creatorcontrib><creatorcontrib>Mintz, Jim</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koek, Ralph J</au><au>Yerevanian, Boghos I</au><au>Mintz, Jim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2012-12-20</date><risdate>2012</risdate><volume>143</volume><issue>1</issue><spage>27</spage><epage>33</epage><pages>27-33</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><coden>JADID7</coden><abstract>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>22749157</pmid><doi>10.1016/j.jad.2012.05.053</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-0327 |
ispartof | Journal of affective disorders, 2012-12, Vol.143 (1), p.27-33 |
issn | 0165-0327 1573-2517 |
language | eng |
recordid | cdi_proquest_miscellaneous_1364765610 |
source | Applied Social Sciences Index & Abstracts (ASSIA); Elsevier |
subjects | Adult Adult and adolescent clinical studies Affective disorders Aged Anticonvulsants Anticonvulsants - therapeutic use Antipsychotic Agents - therapeutic use Antipsychotic drugs Antipsychotics Attempted suicide Benzodiazepines - therapeutic use Biological and medical sciences Bipolar affective disorder Bipolar disorder Bipolar Disorder - drug therapy Bipolar disorders Carbamazepine Conjunction Data processing Depression Dibenzothiazepines - therapeutic use Divalproex Female Hospitalization Hospitals Humans Lithium Male Medical sciences Middle Aged Mood Mood disorders Moods Neuroleptics Neuropharmacology olanzapine Pharmacology. Drug treatments Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology quetiapine Quetiapine Fumarate Retrospective Studies Risk factors Risperidone Risperidone - therapeutic use Suicidal behaviour Suicidal Ideation Suicide Suicide - prevention & control Suicide - psychology Suicide - statistics & numerical data Suicide, Attempted - prevention & control Suicide, Attempted - psychology Suicide, Attempted - statistics & numerical data Veterans |
title | Subtypes of antipsychotics and suicidal behavior in bipolar disorder |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subtypes%20of%20antipsychotics%20and%20suicidal%20behavior%20in%20bipolar%20disorder&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Koek,%20Ralph%20J&rft.date=2012-12-20&rft.volume=143&rft.issue=1&rft.spage=27&rft.epage=33&rft.pages=27-33&rft.issn=0165-0327&rft.eissn=1573-2517&rft.coden=JADID7&rft_id=info:doi/10.1016/j.jad.2012.05.053&rft_dat=%3Cproquest_cross%3E1272723519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1178680841&rft_id=info:pmid/22749157&rfr_iscdi=true |